marketing executive, 45, who died of a stroke caused by the AstraZeneca jab

marketing executive, 45, who died of a stroke caused by the AstraZeneca jab

Daily Mail
By JACK WRIGHT FOR MAILONLINE

PUBLISHED: 12:00, 18 March 2022

Read Full Article Here

https://www.dailymail.co.uk/news/article-10627157/Covid-UK-Marketing-executive-45-died-stroke-caused-AstraZeneca-jab.html

Nicola Weideling, 45, died of a stroke caused by Oxford/AstraZeneca jab
She suffered bleeds on her brain after being hospitalised with blood clots
Her husband has demanded ministers compensate families who lost loved ones
British Heart Foundation said of 438 who developed blood clots, 79 died

The devastated husband of a marketing executive who died of a stroke caused by the Oxford/AstraZeneca Covid jab has demanded that the Government compensate the nearly 80 families who lost loved ones to vaccine-induced blood clots, following his wife’s inquest.

Nicola Weideling suffered catastrophic bleeds on her brain after being hospitalised with blood clots caused by the vaccine which she had received 24 days before dying, a coroner has ruled.

The 45-year-old Oxford University Press executive had complained to her GP about neck pain but she was not diagnosed with vaccine side effects until she was taken to hospital with several other symptoms of blood clots.


Speaking after his late wife’s inquest at Hampshire Coroners Court in Winchester, Kurt Weideling said ministers now need to follow through on their promise to pay affected families £120,000 under the Vaccine Damage Payment programme.

Her family insist those like Mrs Weideling who lost their lives after ‘doing the right thing’ and getting vaccinated should not simply be dismissed as ‘collateral damage’.

The distraught 52-year-old IT manager said: ‘My fundamental problem here is this country is the only Western country I know of which decided it was safe to give this vaccine to people over the age of 40.

‘This is even after other people had already died from blood clots, and they still kept going.